Quinn, Colin H.
Julson, Janet R.
Markert, Hooper R.
Nazam, Nazia
Butey, Swatika
Stewart, Jerry E.
Coleman, Jennifer C.
Markert, James M.
Leavenworth, Jianmei W.
Beierle, Elizabeth A.
Funding for this research was provided by:
National Institutes of Health (5T32GM008361)
National Institutes of Health,United States (T32 CA229102)
Kaul Pediatric Research Institute,United States
Rally Foundation for Childhood Cancer Research
Hyundai Hope On Wheels,United States
Article History
Received: 16 May 2024
Accepted: 22 August 2024
First Online: 5 September 2024
Declarations
:
: Dr J.M. Markert holds equity in Aettis, Inc. (< 8%), a company that holds stocks of oncolytic virus and Treovir, Inc. (25%), a company holding intellectual property and funding clinical trials of oncolytic virus for pediatric brain tumors. A company that Dr J.M. Markert formerly held equity in (< 8%) Catherex, Inc., was purchased in a structured buyout. Dr J.M. Markert has served as a consultant for Imugene. He also holds a fraction of the IP associated with oncolytic virus C134, which is licensed by Mustang Biotech.
: All animal experiments were conducted in accordance with national, international, NIH guidelines, and University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee (IACUC) approval (IACUC 09363).